Category - Markets

H.C. Wainwright downgraded Inotek Pharmaceuticals (NASDAQ:ITEK) to “neutral” from “buy” and slashed its price target to $2 from $7 after a failed Phase 2 trial. The stock closed at 96 cents on July 11. A fixed-dose...

Stifel upgraded Durect (NASDAQ:DRRX) to “buy” from “hold” and raised its price target to $3 from $1.25 and also transitioned coverage to Adam Walsh from Annabel Samimy. The stock closed at $1.59 on July 11. Mr. Walsh...

H.C. Wainwright initiated coverage of Tetraphase Pharmaceuticals (NASDAQ:TTPH) with a “buy” rating and $15 price target. The stock closed at $6.88 on July 10. Analyst Ed Arce writes that he expects a positive readout...

H.C. Wainwright initiated coverage of SeaSpine Holdings (NASDAQ:SPNE) with a “buy” rating and 12-month price target of $15. The stock closed at $12.19 on June 7. SeaSpine is an orthopedic surgical products company...

H.C. Wainwright initiated coverage of Swiss-based ObsEva (NASDAQ:OBSV) with a “buy” rating and $27 price target. The stock closed at $7.50 on June 29. ObsEva is focused on women’s health issues. Its most valuable...

Canaccord Genuity raised its price target for OraSure Technologies (NASDAQ:OSUR) to $18 from $15 after the company entered a four-year, up to $20-million agreement with the Bill & Melinda Gates Foundation, which...

Roth Capital Partners launched coverage of Cutera (NASDAQ:CUTR) with a “buy” rating and $32 price target. The stock closed at $24.50 on June 23. Cutera has built a comprehensive product portfolio, offering multiple...

H.C. Wainwright initiated coverage of Antares Pharma (NASDAQ:ATRS) with a “buy” rating and $5 price target. The stock closed at $3.01 on June 22. Analyst Corey Davis writes that Antares has been a long leader in complex...

H.C. Wainwright launched coverage of Achaogen (NASDAQ:AKAO) with a “buy” rating and $29 price target. The stock closed at $22.11 on June 14. Achaogen has a pipeline of novel antibiotics for serious, hard-to-treat, multi...

H.C. Wainwright initiated coverage of XOMA (NASDAQ:XOMA) with a “buy” rating and $15 price target. The stock closed at $6.86 on June 12th. XOMA owns several premier antibody discovery and development platforms that...